NTRB 8-K
NutriBand Inc. (NTRB)
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported);
| (State or
Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The | ||||
| The |
Item 7.01 Regulation FD Disclosure.
The Company announced today that the Chinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. See Press Release attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are being filed with this Current Report on Form 8-K:
| 99.1 | Press Release issued October 31, 2024 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.
| NUTRIBAND, INC. | ||
| Date: October 31, 2024 | By: | /s/ Gareth Sheridan |
| R: Gareth Sheridan | ||
| Chief Executive Officer | ||
EXHIBIT 99.1
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Chinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.
The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches. The patent number reflects the issuance of Patent No: ZL 202211158031.
The CNIPA issued a prior notice of allowance in September 2024.
About
AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the
abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the
potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs
remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents
granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
About
Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development
is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated
into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking
Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,"
"anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks
and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result
of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal
system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary
financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration
approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any
product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain,
manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development
plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions
and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K for
the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other
filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update
any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact
Information:
Investor Relations
RedChip Companies, Inc.
Dave Gentry
Email: [email protected]
Phone: 1-800-RED-CHIP (733-2447)
or 407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband
Inc.
Phone: 407-377-6695
Email: [email protected]
SOURCE: Nutriband,
Inc.